IT1271688B - Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche - Google Patents

Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche

Info

Publication number
IT1271688B
IT1271688B ITMI941694A ITMI941694A IT1271688B IT 1271688 B IT1271688 B IT 1271688B IT MI941694 A ITMI941694 A IT MI941694A IT MI941694 A ITMI941694 A IT MI941694A IT 1271688 B IT1271688 B IT 1271688B
Authority
IT
Italy
Prior art keywords
hybrid molecules
preparation
pharmaceutical compositions
cancer treatment
hybrid
Prior art date
Application number
ITMI941694A
Other languages
English (en)
Inventor
Antonio Mele
Luigi Rotondaro
Loreto Mario Di
Alatri Laura D
Original Assignee
Menarini Ricerche Sud Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Ricerche Sud Spa filed Critical Menarini Ricerche Sud Spa
Priority to ITMI941694A priority Critical patent/IT1271688B/it
Publication of ITMI941694A0 publication Critical patent/ITMI941694A0/it
Priority to AU32552/95A priority patent/AU3255295A/en
Priority to PCT/EP1995/003060 priority patent/WO1996004305A1/en
Publication of ITMI941694A1 publication Critical patent/ITMI941694A1/it
Application granted granted Critical
Publication of IT1271688B publication Critical patent/IT1271688B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sono descritte delle molecole ibride per il trattamento antitumorale, costituite dalla molecola del G-CSF umano unita ad un anticorpo monoclonale o parti di esso o ad un ligando che riconosce un antigene specifico; è descritto inoltre l'utilizzo delle molecole ibride così costituite per stimolare in vivo una reazione immune contro cellule tumorali esprimenti l'antigene bersaglio.
ITMI941694A 1994-08-04 1994-08-04 Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche IT1271688B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITMI941694A IT1271688B (it) 1994-08-04 1994-08-04 Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
AU32552/95A AU3255295A (en) 1994-08-04 1995-08-01 Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
PCT/EP1995/003060 WO1996004305A1 (en) 1994-08-04 1995-08-01 Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI941694A IT1271688B (it) 1994-08-04 1994-08-04 Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche

Publications (3)

Publication Number Publication Date
ITMI941694A0 ITMI941694A0 (it) 1994-08-04
ITMI941694A1 ITMI941694A1 (it) 1996-02-04
IT1271688B true IT1271688B (it) 1997-06-04

Family

ID=11369444

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI941694A IT1271688B (it) 1994-08-04 1994-08-04 Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche

Country Status (3)

Country Link
AU (1) AU3255295A (it)
IT (1) IT1271688B (it)
WO (1) WO1996004305A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
CZ20033119A3 (cs) 2001-04-24 2005-01-12 Merck Patent Gmbh Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa
US20090130098A1 (en) 2006-01-18 2009-05-21 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP2101805B1 (en) 2007-01-18 2012-11-07 Merck Patent GmbH Integrin ligands for use in treating cancer
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
AU2011278700A1 (en) 2010-07-16 2013-02-28 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0503050A4 (en) * 1990-09-28 1994-07-06 Ortho Pharma Corp Hybrid growth factors
CA2095836C (en) * 1990-11-09 1999-04-06 Stephen D. Gillies Cytokine immunoconjugates

Also Published As

Publication number Publication date
ITMI941694A1 (it) 1996-02-04
ITMI941694A0 (it) 1994-08-04
AU3255295A (en) 1996-03-04
WO1996004305A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
HUP0303976A2 (hu) Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával
FI871718A (fi) Loeslig fosforylerat glukan.
SG52383A1 (en) Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
BG106171A (en) Compositions and uses of et743 for treating cancer
CA2434009A1 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
WO2004074437A3 (en) Compositions and methods for cancer immunotherapy
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
IT1271688B (it) Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
HUP0204216A2 (en) A new use of antibodies as vaccines
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
JPS6485930A (en) Anticancer composition and therapy using monoclonal antibody and il-2 against gd3 ganglioside
CA2368676A1 (en) Sphingomyelin containing preparation

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970828